Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2008-06-10
2008-06-10
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S188100
Reexamination Certificate
active
07384734
ABSTRACT:
The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.
REFERENCES:
patent: 5436131 (1995-07-01), Condra et al.
patent: 5766842 (1998-06-01), Melnick et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 2002/0064838 (2002-05-01), Parkin et al.
patent: 2003/0108857 (2003-06-01), Parkin et al.
patent: 2004/0106106 (2004-06-01), Parkin et al.
patent: WO99/67427 (1999-06-01), None
patent: WO00/78996 (2000-12-01), None
patent: WO02/22076 (2002-03-01), None
patent: WO02/068618 (2002-09-01), None
patent: WO02/099387 (2002-12-01), None
patent: WO03/070700 (2003-08-01), None
patent: WO2004/003512 (2004-01-01), None
patent: WO2004/003514 (2004-01-01), None
Lin, Y.-C., et al., 2003, “Structural basis for distinctions between substrate and inhibitor specifities for feline immunodeficiency virus and human immunodeficiency virus proteases”, J. Virol. 77(12):6589-6600.
Choudhury, S., et al., 2003, “Mutagenesis of the dimer interface residues of tethered and untethered HIV-1 protease result in differential activity and suggest multiple mechanisms of compensation”, Virol. 307:204-212.
Int'l Search Report for PCT/US00/17178, filed Dec. 2000, PCT.
Int'l Search Report for PCT/US01/28754, filed Mar. 2002, PCT.
Int'l Search Report for PCT/US02/01682, filed Sep. 2002, PCT.
Int'l Search Report for PCT/US02/18684, filed Jan. 2003, PCT.
Int'l Search Report for PCT/US03/04362, filed Dec. 2004, PCT.
Int'l Search Report for PCT/US03/21023, filed Jul. 2004, PCT.
Carrillo et al., (1998), “In Vitro Selection and Characterization of Human Immunodefciency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor,”Journal of Virology, 72(9): 7532-41.
Condra et al., (1996), “Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor ,”Journal of Virology, 70(12): 8270-76.
Int'l Search Report for PCT/US03/21335, filed May 2004, PCT.
Craig et al., 1998 “HIV Protease Genotype and Viral Sensitivity to HIV Protease Inhibitors Following Saquinavir Therapy”,AIDS, 12: 1611-1618.
Dreyer GB, et al.“A Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically”Biochemistry(1993) 32:937-947.
J. Eron, et al., (1995) Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors,5th Conference on Retroviruses and Opportunistic Infections.
Genbank Accession No. P12497 POL Polyprotein (2004).
Genbank Accession No. AF324493 HIV-1 vector pNL4 . . . [gi:12831134] (2001).
Gervaix, et al., (1997), “A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility in Vitro,”Proc. Natl. Acad. Sci. USA, 94:4653-4658.
Gong et al., (2000), “In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632,”Antimicrobial Agents and Chemotherapy, 44(9): 2319-26.
Gunthard, et al., (1998), “Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1polFrom Clinical Samples,”Aids Research and Human Retroviruses.14(10): 869-876.
Haubrich et al., (2001), “CCTG 575: A Randomized. Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy,”Antiviral Therapy, 6(Supplement 1): 63.
Hazuda, et al., 2000 “Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells,” Science 287: 646-650.
Herrmann, et al., (1997), “A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity,”Ann. NY Acad Sciences, 284: 632-637.
Hertogs, et al., (1998), “A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs,”Antimicrobial Agents and Chemotherapy, 42(2): 269-276.
Hill, A. et al. (1998) “Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar,”Int. Conf. AIDS12:812, (Abstract No. 6).
Hirsch, et al., (2000), “Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection”JAMA, 283(18): 2417-26.
Katzenstein et al., (2002), “Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364,” Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection,2002 9thConference on Retroviruses and Opportunistic Infections, Session 77 Poster Session 591-T.
Katzenstein et al., (2002), “The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy”2002 9thConference on Retroviruses and Opportunistic Infections, Session 28 Poster Session 129.
Kempf et al., (2001), “Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients,”Journal of Virology, 75(16): 7462-69.
Kim, (1995) “Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme,”J. Am. Chem. Soc., 117: 1181-1182.
Lambert DM, et al. (1992) “Human Immunodeficiency Virus Type 1 Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells”Anit Microb Agents Chem36:982-98.
Larder, et al., (1995) “Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy,”Science, 269, 696-699.
Lazdins, et al., (1997) “In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study wits Other Relevant HIV Protease Inhibitors,”J Infec. Dis., 175: 1063-1070.
Livingston, (1995) “Weak Binding of VX-478 tc Human Plasma Proteins and Implications for Anti-Humar Immunodeficiency Virus Therapy,”J Infec. Dis., 172:1.238-124.
Maguire et al., (2002), “Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors,”Antimicrobial Agents and Chemotherapy, 46(3): 731-738.
Mahalingam, et al., (1999) “Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease,”Biochem., 263: 1-9.
Miller M, et al. (1989) Structure of Complex of Synthetic HIV-lj Protease with a SubstrateBased Inhibitor at 2.3 A Resolution,Science246:1149-1152.
Mohri H, et al. (1993) “Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients,”PNAS90:25-29.
Murphy, et al., (1999) “Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection”J. Infec. Dis., 179: 808-81 E.
Najera I, et al. (1994) “Natural Occurrence of Drug ResistancE Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates,”Aids Res Hum Retroviruses10
Chappey Colombe
Parkin Neil T.
Petropoulos Christos J.
Jones Day
Monogram Biosciences, Inc.
Parkin Jeffrey S.
LandOfFree
Compositions and methods for determining the susceptibility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for determining the susceptibility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for determining the susceptibility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2801466